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Indole alkaloids have attracted the attention of synthetic chemists 
because of their intriguing structural features and remarkable 
bioactivities. This interest is perhaps best represented by the Vinca 
alkaloid vinblastine (1), isolated from Catharanthus roseus, which is 
currently among the foremost drugs used to combat cancer.[1] 
However, de novo synthesis of novel vinblastine analogues remains 
a daunting task due to its highly complex structure. Consequently, 
the discovery of simpler bioactive Aspidosperma alkaloids is of high 
interest to facilitate the discovery of new anti-cancer agents. Not 
surprisingly, intensive synthetic efforts have been directed towards 
the synthesis of vindoline (2),[2] or simpler Aspidosperma alkaloids 
such as aspidospermidine (3)[3] and vincadifformine (4).[4]  
In 2008, Kam and co-workers reported the isolation of seven 
new Aspidosperma indole alkaloids, jerantinine A-G, from a leaf 
extract of the Malayan plant Tabernaemontana corymbosa.[5] 
Among them was jerantinine E (5), which is structurally related to 
vincadifformine (4) but has a more oxidized indole core. The 
jerantinines displayed significant cytotoxic activity (half maximal 
inhibitory concentration; IC50 = 0.27-0.96 g/L (0.70-2.50 M)) 
against human KB cells, which is rare among simple Aspidosperma 
alkaloids. Nevertheless, the mode of action for the cytotoxicity of 
the jerantinines is currently unknown. Furthermore, the highly 
oxygenated core of the jerantinines renders them challenging 
synthetic targets and a total synthesis of jerantinines A-G has not yet 
been reported. 
Herein, we describe the first total synthesis of (±)-jerantinine 
E (5) in 17 steps and 15.7% overall yield from -valerolactam (10). 
The availability of a significant amount of the natural product 
permitted the separation of the enantiomers, in-depth biological 
evaluation of the cytotoxic activity in various human cancer cell 
lines, as well as a first investigation on the origin of the observed 
cytotoxicity.  
 
Figure 1. Vinca and Aspidosperma alkaloids. 
As shown in our retrosynthesis (Scheme 1, A), we envisaged 
that the free hydroxyl group of jerantinine E (5) could be generated 
via selective demethylation during the last step of the total synthesis. 
This strategy would simplify the synthesis by avoiding a multi-step 
hydroxyl group protecting/deprotecting sequence. We expected this 
selective methyl group removal to proceed under oxidative 
conditions due to the presence of the electron-rich nitrogen in the 
para position.[6] As such, the indole core could be oxidized to the 
corresponding iminoquinone followed by in situ reduction to give 5. 
We next planned to build-up the e-ring system by a bis-alkylation 
and to install the methyl ester group on the c-ring via acylation using 
Mander's reagent. This ring formation/acylation sequence was 
developed during the synthesis of Aspidosperma alkaloids by Rawal 
and co-workers, albeit with a less oxygenated indole core.[3d] The 
requisite starting material for this sequence could be generated 
through N-protecting group removal and deoxygenation of 
intermediate 6. Tetracyclic product 6 was envisaged to be accessed 
by a selective cyclization (formal homo-Nazarov reaction) of 
aminocyclopropane 7, previously developed in our group,[7] forming 
the central ring system c. Cyclization precursor 7 would finally be 
obtained by adding an organometallic reagent derived from 
commercially available indole 9 onto Weinreb amide 8. 
Our synthesis commenced with the coupling of Weinreb amide 
8, obtained in seven steps and 51% overall yield from commercially 
available -valerolactam (10),[7] and the bis-lithiated organolithium 
reagent derived from N-carboxy indole 11 (Scheme 1, B). Selecting 
the carboxylate as N-indole protecting group had a dual purpose, as 
it directed the lithiation to the C-2 indole position and was readily 
removed during the aqueous work-up. The desired 
aminocyclopropane 7 was obtained in 72% yield. The formal homo-
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Nazarov cyclization of 7 afforded the cis-diastereoisomer of 6 
exclusively in 85% yield with high C-3 regioselectivity.[8]  
At this point of the synthesis, four of the five ring systems of 
jerantinine E (5) were installed and we turned our attention to the 
formation of the e-ring. Deoxygenation of the ketone was 
unexpectedly challenging however, and the reported one-step 
reduction by Wenkert and co-workers led only to decomposition of 
the starting material.[9] Thus, a two-step procedure was devised to 
remove the ketone functionality. Alcohol 12 was obtained in 96% 
yield employing lithium aluminium hydride under mild conditions. 
We reasoned that an ionic reduction could be ideal at this stage to 
remove the hydroxyl group, as a facile carbocation formation can be 
envisaged due to the highly electron-rich adjacent indole ring 
system. Indeed, treatment of alcohol 12 with boron trifluoride 
etherate at low temperature led to carbocation formation, which 
upon triethylsilane mediated hydride transfer gave intermediate 13 
in 93% yield. Compound 13 was highly unstable under air and the 
subsequent transformations, including Cbz-removal and Rawal’s 
three-step procedure,[3d] had to be completed in one-pot while 
carefully using Schlenk techniques. Although liquid 
chromatography-mass spectrometry analysis of the reaction progress 
indicated that Cbz-deprotection, alkylation, mesylation and base-
mediated ring-closure were working, we were unable to isolate the 
desired pentacyclic compound 14 as it immediately decomposed 
into several unidentifiable products during work-up. 
At this point, it became clear that a new approach avoiding 
highly electron-rich intermediates and reactive imines, such as 14, 
had to be designed to gain access to jerantinine E (5). We speculated 
that these objectives could be realized by introducing the electron-
withdrawing ester group present on the natural product prior to the 
instalment of the last ring system (Scheme 1, C). Thus, the 
presumably reactive imine double bond would migrate into 
conjugation with the ester group upon closure of the fifth ring 
system.  
To test this hypothesis, we made use of the facile carbocation 
formation through the treatment of alcohol 12 with boron trifluoride 
etherate. The carbocation intermediate was reacted with 
trimethylsilylcyanide and the resulting nitrile product was 
transformed into ester 15 via Pinner methanolysis, Cbz-deprotection 
and alkylation with 2-bromoethanol. Gratifyingly, intermediate 15 
successfully underwent the ring-closing procedure, generating 
pentacyclic product 16 in 85% yield. As postulated, the presence of 
the ester group facilitated double bond migration into conjugation, 
producing a perfectly stable compound. Finally, selective 
demethylation of 16 was possible via cerium ammonium nitrate 
mediated oxidation followed by in situ reduction with sodium 
dithionite to give jerantinine E (5) in 79% yield. Thus, the first total 
synthesis of jerantinine E (5) was accomplished in 17 steps and a 
15.7% overall yield starting from -valerolactam (10). 
 
 
 
Scheme 1. Retrosynthetic analysis (A), initial approach (B) and final (C) synthetic route for the total synthesis of jerantinine E (5). 
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With significant amounts of jerantinine E (5) in hand, we 
focused our attention on exploring its potential as an anticancer 
agent. Considering that breast and lung cancers are among the most 
frequent and fatal types of this disease,[10] two human-derived 
breast- and lung-cancer cell lines were selected to investigate the 
cytotoxic activity of jerantinine E (5). A first moderately invasive 
cell line (MCF-7) was selected from breast ductal carcinoma in 
conjunction with a second highly invasive breast cancer cell line 
(MDA-MB-231).[11] The human adenocarcinoma cell line (A549) 
derived from alveolar epithelial cells and adenosquamous carcinoma 
cell line (HTB-178)[12] were chosen to serve as lung cancer model 
cell lines. The two enantiomers of jerantinine E (5) were first 
separated by chiral chromatography and their cytotoxic activity 
examined separately. The cellular assays showed that only naturally 
occurring (-)-jerantinine E (5) was significantly bio-active (Figure 
2).[13] 
 
Figure 2. Effect of (-)-jerantinine E (5) on the survival of breast cancer 
cells (A (24 h exposure) and B (72 h exposure) black bar: MDA-MB-
231, grey bar: MCF-7) and lung cancer cells, (C (24 h exposure) and 
D (72 h exposure) black bar: A549, grey bar: HTB-178). Please see 
the Supporting Information for additional experimental details. 
Both breast cancer cell lines gave comparable inhibition values 
for cell growth after 24 and 72 hours (Figure 2A and 2B) having 
IC50-values between 1.7 to 2.3 μg/mL (4.4 to 6.0 M). The 
screening assay in the two lung cancer cell lines revealed that (-)-
jerantinine E (5) exhibits greater cytotoxicity against the 
adenocarcinoma A549 cell line compared to adenosquamous HTB-
178 cells at both, 24 and 72 hours (Figure 2C and 2D). In the four 
tested human cancer cell lines, (-)-jerantinine E (5) displayed the 
highest cytotoxic effect in the A549 cell line with an IC50 after 24 
and 72 hours of exposure of 1.6 and 0.4 μg/mL (4.2 and 1.0 M), 
respectively (Figure 2C and 2D). 
After studying the cytotoxic activity profile for jerantinine E (5), 
we set out to elucidate possible mechanisms for the observed cell 
growth inhibition. First, a cell migratory assay was carried out with 
the above described human-derived cancer cell lines. Inhibition of 
cell migration ranging between 50 and 90% was observed in all four 
cancer cell lines after 15 hours of exposure to 2 and 6 µg/mL of 
jerantinine E (5).[14] Second, an impedance study of jerantinine E (5) 
against the L-929 (mouse fibroblast) cell line was carried out. In this 
assay, cells are placed on a gold electrode plate and treated with the 
test compound at their IC90 concentration. During a five day time 
period, the change in impedance, due to changes in the 
morphological state of the cells upon compound exposure, is 
measured. Through cluster analysis, the obtained data can then be 
matched to the data of a reference compound with a known 
target.[15] Using this approach, we found that jerantinine E (5) 
displayed an impedance profile in accordance with reference 
compounds, such as colchicine, which affects the microtubule 
network. An immunofluorescent staining assay was then carried out 
(Figure 3) with PtK2 kidney cells to confirm this possible mode of 
action. As shown in Figure 3B, multi-lobed nuclei were observed 
after exposing PtK2 kidney cells to 2 g/mL jerantinine E (5). 
Furthermore, disruption of the microtubule network already became 
apparent at this stage and is nearly complete at higher concentration 
(Figure 3C and 3D). Such observations further suggested 
microtubule disruption as a plausible mode of action. To confirm 
this hypothesis, the ability of both enantiomers and racemic 
jerantinine E (5) to inhibit tubulin polymerization was studied on the 
purified tubulin. The assay showed (-)-jerantinine E (5) to be a 
potent inhibitor of tubulin polymerization with an IC50-value of 0.17 
μg/mL (0.45 M).[14] It is noteworthy that (-)-jerantinine E (5) 
proved to be even slightly more active than the known microtubule 
skeleton disruptor colchicine.   
 
Figure 3. Immunofluorescent staining of untreated PtK2 kidney cells 
(A) and cells exposed to 2 g/mL (B), 6 g/mL (C) and 10 g/mL (D) 
jerantinine E (5) showing the effect on microtubules (green) and the 
cell nucleus (blue). Please see the Supporting Information for 
additional experimental details.  
In conclusion, we have described the first total synthesis of the 
indole alkaloid jerantinine E (5) in 17 steps and 15.7% overall yield 
starting from -valerolactam (10). An efficient and highly selective 
formal homo-Nazarov cyclization of an aminocyclopropane was 
used to give access to four of the five rings contained in the complex 
polycyclic core of the natural product. A novel strategy to install the 
ester group onto the highly sensitive indole alkaloid core was 
devised, addressing the challenges represented by the highly 
oxygenated and reactive core of the molecule. Lastly, a late-stage 
selective demethylation led to an efficient synthetic sequence. The 
total synthesis enabled us to investigate the biological profile of 
jerantinine E (5). The cytotoxic activity of the natural product was 
determined in several human-derived breast and lung cancer cell 
lines, displaying for instance an IC50 value of 0.4 µg/mL (1.0 M) in 
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the A549 lung cancer cell line. Investigations into the mode of 
action suggested that jerantinine E (5) acts via disruption of the 
microtubule network, as indicated by its potent inhibitory activity 
displayed in tubulin polymerization. Future work will focus on the 
synthesis of analogues for a detailed structure-activity relationship 
study with the goal of finding compounds with improved activity 
and potency. Additional experiments to elucidate the exact origin of 
the observed microtubule disruption will also be considered to 
further understand the source of the observed cytotoxicity.   
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1. List of Abbreviations 
 
EtOAc   Ethyl acetate  
DMTMM  Dimethoxytriazin-N-methylmorpholinium chloride 
DCM   Dichloromethane  
NMM   N-Methylmorpholine 
THF   Tetrahydrofuran 
Cbz   Carboxybenzyl  
Ultra   CH2Cl2:MeOH 3:1 (v/v) with 5% NH3 (aq., 25%) 
GHP   General hydrogenolysis procedure 
 
 
2. General Methods 
 
Technical grade solvents were used for quantitative flash chromatography. HPLC grade 
solvents purchased from Sigma-Aldrich or freshly distilled solvents were used for flash 
chromatography for compounds undergoing full characterization. Reaction solvents were 
dried by passage over activated alumina under nitrogen atmosphere (H2O content < 30 ppm, 
Karl-Fischer titration). Commercially available reagents were purchased from Acros, Aldrich, 
Fluka, VWR, Aplichem or Merck and used without any further purification. Chromatographic 
purification was performed as flash chromatography using Macherey-Nagel silica 40-63, 60 
Å, using the solvents indicated as eluent with 0.1-0.5 bar pressure. TLC was performed on 
Merck silica gel 60 F254 TLC plates and visualized with UV light and permanganate stain. 
Melting points were measured on a calibrated Büchi B-540 melting point apparatus using 
open glass capillaries. 1H NMR spectra were measured on a Brucker DPX-400 400 MHz 
spectrometer, all signals are reported in ppm with the corresponding internal solvent peak or 
TMS as standard. The data is being reported as (s = singlet, d = doublet, t = triplet, q = 
quadruplet, qi = quintet, m = multiplet or unresolved, br = broad signal, coupling constant(s) 
in Hz, integration; interpretation). 13C NMR spectra were carried out with 1H-decoupling on a 
Brucker DPX-400 100 MHz. All signals are reported in ppm with the corresponding internal 
solvent signal or TMS as standard. Infrared spectra were obtained on a JASCO FT-IR B4100 
spectrophotometer with an ATR PRO410-S and a ZnSe prisma and are reported as cm-1 (w = 
weak, m = medium, s = strong, sh = shoulder). High resolution mass spectrometric 
measurements were performed by the mass spectrometry service of ISIC at the EPFL on a 
MICROMASS (ESI) Q-TOF Ultima API. Optical rotatory measurements were performed on 
a JASCO P-2000 Polarimeter.  
 
 
3. General Hydrogenolysis Procedure (GHP)  
 
A solution of of Cbz-protected amine (0.02 M in ethanol) was charged at room temperature 
with Pd/C (0.1 eq.) and hydrogen gas was bubbled through the mixture until full conversion 
of the starting material was observed by TLC.1 The suspension was filtered through a short 
plug of celite (prewashed with DCM) using additional amounts of DCM and EtOAc to ensure 
that complete product elution form the plug was achieved. The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. No further purification was necessary.  
 
                                                 
1 A batch to batch Pd/C dependency for the reaction time was observed. It is consequently important to carefully 
monitor the reaction via TLC analysis.  
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4. Total Synthesis of Jerantinine E 
 
Benzyl 5-ethyl-3,4-dihydropyridine-1(2H)-carboxylate (18) 
 
 
 
Following a slight modification of a reported procedure,2 a 1.6 M solution of nBuLi in hexane 
(90.0 mL, 144 mmol, 2.20 eq.) was added dropwise to a solution of δ-valerolactam (10, 6.50 
g, 65.6 mmol, 1.00 eq.) in dry THF (100 mL) at 0 °C. The resulting yellow solution was 
stirred at 0 °C for 30 minutes, after which freshly distilled ethyl iodide (7.91 mL, 98.0 mmol, 
1.50 eq.) was added. The reaction mixture was stirred for an additional 20 minutes at 0 °C 
before benzyl chloroformate (9.83 mL, 68.8 mmol, 1.05 eq.) was added. The reaction mixture 
was stirred for 30 minutes at 0 °C, diluted with diethyl ether (170 mL) and washed with brine 
(2 x 70 mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by flash column chromatography (pentane:EtOAc 5:1) to 
yield lactam 17 (12.4 g, 47.5 mmol, 72%) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
7.46-7.39 (m, 2 H, ArH), 7.39-7.28 (m, 3 H, ArH), 5.27 (s, 2 H, OCH2), 3.85-3.76 (m, 1 H, 
NCH2), 3.73-3.64 (m, 1 H, NCH2), 2.40-2.29 (m, 1 H, CHCO), 2.07-1.73 (m, 4 H; CH2CH2), 
1.58-1.44 (m, 2 H, CH2), 0.96 (t, 3 H, J = 7.5 Hz, CH3). 
13C NMR (CDCl3, 100 MHz) δ 174.3, 
154.4, 135.6, 126.8, 128.3, 128.1, 68.4, 46.2, 45.4, 25.5, 24.2, 21.7, 11.5. The values of the 
NMR spectra are in accordance with reported literature data.3 
 
Following a reported procedure,4 sodium borohydride (1.27 g, 34.0 mmol, 1.20 eq.) was 
added portionwise to a solution consisting of Cbz-protected lactam (17, 7.40 g, 28.3 mmol, 
1.00 eq.) and methanol (150 mL) at 0 °C. The reaction mixture was stirred at 0 °C for two 
hours and then quenched with ice water (10 mL). The mixture was diluted with water (100 
mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with 
brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo. The resulting colorless 
oil was dissolved in dry diethyl ether (75 mL) and concentrated sulfuric acid (30 µL) was 
added at room temperature. The reaction mixture was stirred at room temperature for 30 
minutes, then quenched with solid K2CO3 and dried with MgSO4. The suspension was filtered 
and concentrated in vacuo to afford 18 (6.82 g, 27.8 mmol, 98%) as a colorless oil. 1H NMR 
(CDCl3, 400 MHz) δ 7.42-7.28 (m, 5 H, ArH), 6.70 (s, 0.45 H, alkene-H rotamer A), 6.60 (s, 
0.55 H, alkene-H rotamer B), 5.19 (s, 1.1 H, OCH2 rotamer B), 5.17 (s, 0.9 H, OCH2 rotamer 
A), 3.57 (m, 2 H, NCH2), 2.07-1.94 (m, 4 H), 1.82 (m, 2 H), 1.06-0.97 (m, 3 H; CH3). 
13C 
NMR (CDCl3, 100 MHz) (rotamers!) δ 153.4, 153.0, 136.5, 136.4, 128.3, 127.9, 127.8, 121.0, 
120.6, 119.1, 118.7, 67.1, 67.0, 41.9, 41.8, 28.1, 28.1, 24.8, 24.7, 21.6, 21.6, 12.6, 12.4. The 
values of the NMR spectra are in accordance with reported literature data.2 
 
 
 
 
                                                 
2 P. A. Grieco, M. D. Kaufman, J. Org. Chem. 1999, 64, 7586-7593. 
3 F. De Simone, J. Gertsch, J. Waser, Angew. Chem. Int. Ed. 2010, 49, 5767-5770. 
4 Y. Takeuchi, K. Azuma, M. Oshige, H. Abe, H. Nishioka, K. Sasaki, T. Harayama, Tetrahedron 2003, 59,  
  1639-1646. 
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2-((Benzyloxy)carbonyl)-6-ethyl-2-azabicyclo[4.1.0]heptane-7-carboxylic acid (20) 
 
 
 
Following a slight modification of a reported procedure,5 a solution of ethyl diazoacetate 
(6.05 mL, 57.1 mmol, 4.00 eq.) in dry DCM (14 mL) was added to a solution of enamine 18 
(3.50 g, 14.3 mmol, 1.00 eq.) and copper triflate (I) toluene complex (148 mg, 0.286 mmol, 
0.0200 eq.) in DCM (14 mL) over 18 h (1.3 mL/h) via syringe pump. After the addition was 
complete, the reaction was concentrated in vacuo and purified by flash column 
chromatography (pentane:EtOAc 15:1 to pentane:EtOAc 10:1) to yield 19 (3.67 g, 11.3 
mmol, 78%) as colorless oil.  
 
Following a reported procedure,1 the mixture of exo and endo esters (19, 2.13 g, 6.43 mmol, 
1.00 eq.) in DCM (25 mL) was treated at -20 °C with freshly distilled BF3-etherate (210 µL, 
0.964 mmol, 0.150 eq.). The reaction was allowed to warm up to 0 °C over a two hour time 
period during which the isomerization went to completion. The reaction was quenched with 
triethylamine (1.5 mL), diluted with diethyl ether (75 mL) and extracted with water (50 mL). 
The aqueous layer was extracted with additional portions of diethyl ether (2 x 30 mL) and the 
combined organic layers were washed with brine (50 mL), dried over MgSO4, filtered and 
concentrated in vacuo to afford a pale yellow oil (2.13 g, 6.43 mmol, quant.), which was used 
directly in the next step. Thus, the ester-intermediate (2.13 g, 6.43 mmol, 1.00 eq.) was 
dissolved in a mixture of H2O:THF:EtOH 1:1:3 (total volume = 35 mL) and cooled to 0 °C. 
Next, NaOH (2.31 g, 57.8 mmol, 9.00 eq.) was added portionwise and the resulting solution 
was heated at 60 °C for 90 minutes. The mixture was diluted with water (30 mL) and 
extracted with diethyl ether (3 x 30 mL). The combined organic layers were washed with 
water (2 x 30 mL). The combined aqueous layers were acidified with 1.0 M aq. HCl to pH = 
2, followed by extraction with DCM (3 x 40 mL). The combined organic layers were dried 
over MgSO4, filtered and concentrated in vacuo to give 20 (1.87 g, 6.17 mmol, 96% over two 
steps) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.39-7.21 (m, 5 H, ArH), 5.23-5.09 (m, 
2 H, OCH2), 3.86 (dt, 0.7 H, J = 12.5, 3.1 Hz, NCH2 rotamer A), 3.73 (m, 0.3 H, NCH2 
rotamer B), 3.55 (d, 0.3 H, J = 3.5 Hz, NCH rotamer B), 3.49 (d, 0.7 H, J = 3.6 Hz, NCH 
rotamer A), 2.77 (dt, 0.3 H. J = 12.5, 1.7 Hz, NCH2 rotamer B), 2.66 (dt, 0.7 H, J = 12.5, 3.4 
Hz, NCH2 rotamer A), 2.05 (m, 1 H, CHCO), 1.93-1.12 (m, 6 H, CH2), 0.99 (t, 1 H, J = 7.2 
Hz, CH3 rotamer B), 0.93 (t, 2 H, J = 7.4 Hz, CH3 rotamer A). 
13C NMR (CDCl3, 100 MHz) 
(rotamers!) δ 177.2, 176.9, 156.2, 136.5, 128.5, 128.4, 128.1, 127.7, 127.2, 67.1, 67.0, 44.9, 
44.8, 41.5, 41.1, 34.7, 34.0, 31.1, 30.6, 25.9, 25.7, 21.5, 21.3, 20.9, 10.3, 9.9. The values of 
the NMR spectra are in accordance with reported literature data.2 
 
 
 
 
 
 
 
                                                 
5 R. Beumer, C. Bubert, C. Cabrele, O. Vielhauer, M. Pietzsch, O. Reiser, J. Org. Chem. 2000, 65, 8960-8969. 
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Benzyl 6-ethyl-7-(methoxy(methyl)carbamoyl)-2-azabicyclo[4.1.0]heptane-2-carboxylate 
(8) 
 
 
 
Freshly prepared dimethoxytriazin-N-methylmorpholinium chloride6 (DMTMM, 2.43 g, 8.79 
mmol, 1.50 eq.) was added to a solution consisting of carboxylic acid 20 (1.78 g, 5.86 mmol, 
1.00 eq.) and dry THF (20 mL). The resulting white suspension was stirred at room 
temperature for one hour, after which N,O-dimethylhydroxylamine hydrochloride (572 mg, 
5.86 mmol, 1.00 eq.) and N-methylmorpholine (NMM, 1.29 mL, 11.7 mmol, 2.00 eq.). The 
reaction mixture was stirred for 48 hours at room temperature followed by quenching with 5% 
aq. citric acid (30 mL). The mixture was extracted with diethyl ether (3 x 30 mL) and the 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
crude oil was purified by flash column chromatography (hexane:EtOAc 4:1) to yield 
Weinreb-amide 8 (1.97 g, 5.68 mmol, 97%) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
7.35-7.19 (m, 5 H, ArH), 5.23 (d, 0.8 H, J = 12.9 Hz, OCH2 rotamer A), 5.14 (d, 0.2 H, J = 
12.5 Hz, OCH2 rotamer B), 5.07 (d, 1 H, J = 13.0 Hz, OCH2), 3.84 (dt, 0.8 H, J = 12.5, 3.4 
Hz, NCH2 rotamer A), 3.71 (m, 0.2 H, NCH2, rotamer B), 3.64 (s, 0.6 H, OCH3 rotamer B), 
3.58-3.52 (m, 2.4 H, OCH3 rotamer A and NCH rotamer B), 3.49 (d, 0.8 H, J = 3.7 Hz, NCH 
rotamer A), 3.15 (s, 0.6 H, NCH3 rotamer B), 3.12 (s, 2.4 H, NCH3 rotamer A), 2.73 (t, 0.2 H, 
J = 11.7 Hz, NCH2 rotamer B), 2.64 (dt, 0.8 H, J = 12.5, 2.2 Hz, NCH2 rotamer A), 2.09-1.87 
(m, 2 H, CHCO and CH2), 1.77-1.54 (m, 4 H, CH2), 1.36 (m, 1 H, CH2), 0.85 (t, 3 H, J = 7.4 
Hz, CH3). 
13C NMR (CDCl3, 100 MHz) δ (rotamers!) 171.2, 156.2, 136.8, 128.2, 128.1, 
127.8, 127.8, 127.4, 127.0, 66.8, 66.5, 61.2, 42.9, 42.7, 41.5, 41.0, 33.0, 32.4, 29.1, 28.5, 26.0, 
25.9, 25.2, 21.6, 10.3. The values of the NMR spectra are in accordance with reported 
literature data.2 
 
 
Benzyl 7-(5,6-dimethoxy-1H-indole-2-carbonyl)-6-ethyl-2-azabicyclo[4.1.0]heptane-2-
carboxylate (7) 
 
 
 
Following a slight modification of a reported procedure,7 commercially available 5,6-
dimethoxyindole (9, 180 mg, 1.02 mmol, 1.00 eq.) was dissolved in dry THF (7.0 mL). The 
colorless solution was cooled to 0 °C and a 1.6 M solution of nBuLi in hexane (760 µL, 1.22 
mmol, 1.10 eq.) was added dropwise. The reaction mixture was heated at reflux for 2 hours 
and then cooled back to 0 °C to bubble CO2 into the reaction mixture for 45 minutes. The 
resulting suspension was quenched with water (10 mL) at 0 °C and extracted with diethyl 
ether (3 x 10 mL). The combined organic layers were washed with water (20 mL). The 
                                                 
6 M. Kunishima, C. Kawachi, F. Iwasaki, K. Terao, S. Tani, Tetrahedron Lett. 1999, 40, 5327-5330. 
7 D. A. Shirley, P. A. Roussel, J. Am. Chem. Soc. 1953, 75, 375-378. 
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combined aqueous layers were acidified with 1.0 M aq. HCl to pH = 2, followed by extraction 
with diethyl ether (3 x 15 mL). The three combined diethyl ether layers were dried over 
MgSO4, filtered and concentrated in vacuo (for only five minutes to avoid potential 
decarboxylation) to yield carboxylic acid protected indole 11 (224 mg, 1.01 mmol, quant.) as 
a white solid, which was used in the next step without any further purification. 1H NMR 
(CDCl3, 400 MHz) δ 7.80 (s, 1 H, ArH), 7.53 (d, 1 H, J = 3.7 Hz, ArH), 7.04 (s, 1 H, ArH), 
6.57 (d, 1 H, J = 3.6 Hz, ArH), 4.00 (s, 3 H, OCH3), 3.95 (s, 3 H, OCH3). 
13C NMR (CDCl3, 
100 MHz) δ 155.7, 148.2, 147.1, 129.5, 124.2, 123.6, 109.5, 102.9, 99.5, 56.5, 56.3. 
 
 
 
A 1.6 M solution of tBuLi in pentane (6.95 mL, 11.1 mmol, 2.20 eq.) was added dropwise to a 
solution of freshly prepared carboxylic acid protected indole 11 (1.23 g, 5.56 mmol, 1.10 eq.) 
and lithium chloride8 (236 mg, 5.56 mmol, 1.10 eq.) in dry THF (26 mL) at -78 °C. The 
mixture was stirred for 3 hours at -78 °C and then transferred via cannula into a,  to 78 °C pre-
cooled, solution of Weinreb-amide 8 (1.77 g, 5.11 mmol, 1.00 eq.) dissolved in dry THF (13 
mL). The reaction mixture was slowly allowed to warm up to -20 °C over a 3.5 hour time 
period and then kept at -20 °C for 30 minutes. The reaction was quenched by transferring it 
via cannula to saturated aq. NaHCO3 (75 mL) pre-cooled to 0 °C. The mixture was stirred for 
10 minutes at 0 °C, after which the ice/water bath was removed and stirring was continued for 
an additional 20 minutes. The aqueous mixture was extracted with diethyl ether (4 x 50 mL) 
and the combined organic layers were dried over MgSO4, filtered and treated with deactivated 
silica gel prior to removing the solvent in vacuo. The crude product was purified by flash 
column chromatography (pentane:EtOAc 4:1 to 3:1), dry loading the crude, affording 7 (1.69 
g, 3.65 mmol, 72%) as a colorless oil (Rf in pentane:EtOAc 7:3 = 0.64). As NMR analysis of 
7 was difficult due to the rotamers caused by the Cbz-protecting group, the above described 
general hydrogenolysis procedure (GHP) was utilized on a small aliquot of 7 to yield free 
amine 21 for a simplified compound analysis of the resulting light yellow oil. Rf (DCM:Ultra 
4:1) = 0.57. 1H NMR (CD2Cl2, 400 MHz): δ 7.10 (bs, 1 H, NH), 7.07 (s, 1 H, ArH), 6.79 (s, 1 
H, ArH), 4.87 (s, 1 H, ArH), 3.94 (s, 3 H, OCH3), 3.86 (s, 3 H, OCH3), 3.27 (d, 1 H, J = 17.0 
Hz, NHCH), 3.16-3.08 (m, 1 H, NHCH2), 2.90 (td, 1 H, J = 11.8, 2.7 Hz, NHCH2), 2.21 (d, 1 
H, J = 17.2 Hz, COCH), 1.82-1.55 (m, 4 H) 1.42-1.21 (m, 3 H), 0.81 (t, 3 H, J = 7.5 Hz, 
CH2CH3).
 13C NMR (CD2Cl2, 100 MHz) δ 189.9, 151.6, 147.3, 132.6, 132.0, 120.9, 105.8, 
103.7, 92.4, 71.3, 56.6, 56.5, 46.0, 41.0, 39.7, 33.6, 30.9, 22.4, 7.5. IR ν 2935 (w), 2856 (w), 
1658 (m), 1527 (s), 1493 (w), 1464 (w), 1408 (w), 1350 (w), 1318 (w), 1224 (s), 1051 (w). 
HRMS (ESI) C19H25N2O3
+ [M+H]+ calc. = 329.1860; [M+H]+ obs. = 329.1867. 
 
 
 
 
                                                 
8 LiCl was dried under careful flame heating and high vacuum (<0.05 Torr) before it was dissolved in dry THF. 
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Benzyl 4-ethyl-9,10-dimethoxy-6-oxo-2,3,4,4,5,6,7,11-octahydro-1H-
pyrido[3,2]carbazole-1-carboxylate (6) 
 
 
 
A 0.1 M solution of copper(II) triflate in acetonitrile (4.93 mL, 0.493 mmol, 0.200 eq.) was 
slowly added at room temperature to a solution consisting of vinyl cyclopropyl ketone 7 (1.14 
g, 2.47 mmol, 1.00 eq.) and dry acetonitrile (120 mL). The reaction mixture was stirred at 
room temperature for 10 minutes and then quenched by adding saturated aq. NaHCO3 (150 
mL). The mixture was extracted with diethyl ether (3 x 50 mL). The combined organic layers 
were washed with brine (75 mL), dried over MgSO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (pentane:EtOAc 3:1 to 2:1) to 
afford 6 (971 mg, 2.10 mmol, 85%) as a light yellow solid (Rf in pentane:EtOAc 1:1 = 0.50). 
As NMR analysis of 6 was difficult due to the rotamers caused by the Cbz-protecting group, 
the above described general hydrogenolysis procedure (GHP) was utilized on a small aliquot 
of 6 to yield free amine 22 for a simplified compound analysis resulting light yellow oil. Rf 
(DCM:Ultra 3:2) = 0.54. 1H NMR (CD2Cl2, 400 MHz): δ 9.24 (bs, 1 H, NH indole), 7.15 (s, 1 
H, ArH), 6.83 (s, 1 H, ArH), 3.98 (s, 1 H, NCH), 3.88 (s, 3 H, OCH3), 3.87 (s, 3 H, OCH3), 
3.07 (d, 1 H, J = 16.7 Hz, COCH2), 3.02-2.93 (m, 1 H, NHCH2), 2.86-2.74 (m, 1 H, NHCH2), 
2.21 (d, 1 H, J = 16.6 Hz, COCH2), 1.77-1.57 (m, 4 H), 1.56-1.45 (m, 2 H), 1.40-1.29 (m, 1 
H), 0.81 (t, 3 H, J = 7.5 Hz, CH2CH3). 
13C NMR (CD2Cl2, 100 MHz) δ 190.3, 151.8, 146.9, 
134.3, 130.1, 129.1, 119.2, 101.9, 94.8, 57.0, 56.6, 56.4, 45.8, 43.3, 41.2, 33.4, 31.4, 23.3, 8.0. 
IR ν 3271 (w), 2934 (w), 1644 (s), 1627 (s), 1539 (m), 1488 (s), 1463 (m), 1296 (w), 1266 (s), 
1220 (s), 1162 (w), 1012 (w). HRMS (ESI) C19H25N2O3
+ [M+H]+ calc. = 329.1860; [M+H]+ 
obs. = 329.1865. 
 
 
(4,11)-benzyl 4-ethyl-9,10-dimethoxy-2,3,4,5,6,7,11-octahydro-1H-pyrido[3,2-]carbazole-
1-carboxylate (13) 
 
 
 
The Cbz-protected ketone starting material 6 (200 mg, 0.432 mmol, 1.00 eq.) was dissolved in 
dry THF (7 mL), cooled to -78 °C and slowly transferred via cannula to a suspension of 
lithium aluminum hydride (32.8 mg, 0.865 mmol, 2.00 eq.) at -78 °C. The reaction mixture 
was stirred for 2 hours at -78 °C, after which the dry ice/acetone bath was removed to stir the 
reaction for an additional two hours at room temperature. The mixture was cooled to 0 °C and 
quenched by carefully adding a few drops of water. The resulting mixture was filtered through 
S8 
 
a, with THF prewashed, pad of celite and concentrated in vacuo to yield the corresponding 
hydroxy derivative 12 as a white solid.9 Intermediate 12 was dissolved in dry DCM (10 mL) 
and cooled to -78 °C. To the clear colorless solution was added dropwise freshly distilled 
boron trifluoride diethyl etherate (137 µL, 0.519 mmol, 1.2 eq.) to produce a dark red 
solution, which was quickly treated with excess triethylsilane (5.0 mL). The reaction mixture 
was stirred at -78 °C for 10 minutes and then quenched by transferring it via cannula to 
saturated aq. NaHCO3 (20 mL) pre-cooled to 0 °C. The mixture was stirred for 10 minutes at 
0 °C, after which the ice/water bath was removed and stirring was continued for an additional 
20 minutes. The aqueous mixture was extracted with DCM (3 x 20 mL) and the combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product 
was purified by flash column chromatography (pentane:EtOAc 3:1 to 2:1) affording 13 (180 
mg, 0.402 mmol, 93%) as a light beige solid.10 Rf (pentane:EtOAc 3:2) = 0.36. 
1H NMR 
(CDCl3, 400 MHz): 7.63 (bs, 0.6 H, NH rotamer A), 7.61 (bs, 0.4 H, NH rotamer B), 7.47-
7.26 (m, 5 H, ArH), 6.81 (s, 0.6 H, ArH rotamer A), 6.80 (s, 0.4 H, ArH rotamer B), 6.70 (s, 
0.4 H, ArH rotamer B), 6.68 (s, 0.6 H, ArH rotamer A), 5.41-5.16 (m, 3 H, OCH2 and NCH), 
4.15-4.07 (m, 0.6 H rotamer A), 4.07-3.99 (m, 0.4 H rotamer B), 3.88 (s, 1.8 H, OCH3 
rotamer A), 3.87 (s, 1.2 H, OCH3 rotamer B), 3.64 (s, 1.8 H, OCH3 rotamer A), 3.59 (s, 1.2 H, 
OCH3 rotamer B), 2.81-2.69 (m, 1 H), 2.69-2.58 (m, 1 H), 2.57-2.46 (m, 1 H), 1.86-1.24 (m, 8 
H), 0.92 (t, 1.2 H, J = 7.5 Hz, OCH3 rotamer B), 0.86 (t, 1.8 H, J = 7.5 Hz, OCH3 rotamer A). 
HRMS (ESI) C27H33N2O4
+ [M+H]+ calc. = 449.2435; [M+H]+ obs. = 449.2437. 
 
 
3-Ethyl-8,9-dimethoxy-2,3,3,4,5,11,12-octahydro-1H-indolizino[8,1]carbazole (14) 
 
 
 
A Schlenk tube was charged under nitrogen with intermediate 13 (20.0 mg, 0.0446 mmol, 
1.00 eq.) and the above described GHP was carried out for Cbz-group removal. The reaction 
was monitored by HPLC-MS, which indicated full deprotection ([M+H]+ calc. = 315.2607; 
[M+H]+ obs. = 315.2603) after 15 minutes of stirring at room temperature. The Pd-catalyst 
was quickly removed via filtration through a CHROMAFIL® Xtra RC-20/25 syringe filter. 
After washing the filter several times with dry ethanol, the solvent was removed in vacuo. 
Following a slight modification of a reported procedure,11 the free amine was immediately 
dissolved in dry methanol (2.0 mL) in a Schlenk tube under nitrogen. To the resulting solution 
was added 2-bromoethanol (31.6 µL, 0.446 mmol, 10.0 eq.) and dry sodium carbonate (47.0 
mg, 0.446 mmol, 10.0 eq.). The sealed Schlenk tube was stirred at reflux and the reaction was 
monitored by HPLC-MS. The free amine was consumed after 4 hours and HPLC-MS analysis 
indicated the desired alkylation as the main product (HRMS: [M+H]+ calc. = 359.2329; 
[M+H]+ obs. = 359.2338). Thus, the solvent was removed in vacuo and the resulting light 
yellow solid (still in the Schlenk tube) was dissolved in dry DCM (2.0 mL) and cooled to -20 
                                                 
9 The full characterization of one of the two formed hydroxy diastereoisomer (12a) is shown below for the 
transformation 6 to 15. 
10 We observed that intermediate 13 decomposed quickly, even at -20 °C and under argon, and should be used 
immediately for a subsequent transformation.  
11 S. A. Kozmin, T. Iwama, Y. Huang, V. H. Rawal, J. Am. Chem. Soc. 2002, 124, 4628-4641. 
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°C. The solution was treated with methanesulfonyl chloride (6.90 µL, 0.0891 mmol, 2.00 eq.), 
triethylamine (18.7 µL, 0.134 mmol, 3.00 eq.) and then slowly let come to room temperature 
over a 3 hour time period. HPLC-MS analysis indicated formation of the 2-
chloroethylamine12 alkylation product (HRMS: [M+H]+ calc. = 377.1990; [M+H]+ obs. = 
377.2009) as well as some already cyclized product 14 (HRMS: [M+H]+ calc. = 341.2224; 
[M+H]+ obs. = 341.2238). In order to cyclize the remaining chloroethylamine intermediate, 
the mixture was concentrated in vacuo, the resulting yellow solid suspended in dry THF (4.0 
mL) and cooled to 0 °C. Next was added dropwise at 0 °C a 0.3 M potassium tert.-butoxide 
solution in THF (0.300 mL, 0.0892 mmol, 2.00 eq.) and the mixture was stirred overnight for 
16 hours, letting the reaction temperature slowly come to room temperature. HPLC-MS 
analysis indicated full consumption of the remaining chloroethylamine intermediate. Thus, the 
reaction mixture was quenched by adding a few drops of water, diluted with THF (5.0 mL), 
dried over MgSO4, filtered and concentrated in vacuo. Attempts to purify the crude product 
by column chromatography or crystallization were unsuccessful as the product quickly 
decomposed into numerous unidentifiable products during these purification efforts.  
 
 
 
Methyl 4-ethyl-1-(2-hydroxyethyl)-9,10-dimethoxy-2,3,4,5,6,7,11-octahydro-1H-
pyrido[3,2]carbazole-6-carboxylate (15) 
 
 
 
The Cbz-protected ketone starting material (6, 435 mg, 0.940 mmol, 1.00 eq.) was dissolved 
in dry THF (43 mL), cooled to 0 °C and slowly transferred via cannula to a suspension of 
lithium aluminum hydride (71.4 mg, 1.88 mmol, 2.00 eq.) at 0 °C. The reaction mixture was 
stirred overnight for 11 hours at 0 °C and then quenched by carefully adding a few drops of 
water. The mixture was filtered through a, with THF prewashed, pad of celite and 
concentrated in vacuo to yield the two corresponding hydroxy diastereoisomers 12 (420 mg, 
0.904 mmol, 96%, Rf in pentane:EtOAc 1:1 = 0.48 for 12a and 0.44 for 12b) as a white solid. 
Intermediate 12 was stored under argon at -20 °C and aliquots of it were used to investigate 
further transformations. We note that highly pure solvents, reagents and clean glassware are 
required for subsequent reactions utilizing 12, as in certain cases rapid decomposition of this 
sensitive intermediate was observed. It was possible to obtain a pure sample of hydroxy 
diastereoisomer 12a for characterization purposes by flash column chromatography 
(pentante:EtOAc 2:1). Partial degradation of sensitive hydroxy intermediate 12 was however 
observed during flash column chromatography purification. 
 
Hydroxy diastereoisomers 12a: Rf (pentane:EtOAc 1:1) = 0.48. 
1H NMR (CD2Cl2, 400 MHz): 
8.55 (bs, 0.4 H, NH rotamer B), 8.53 (bs, 0.6 H, NH rotamer A), 7.47-7.23 (m, 5 H, ArH), 
                                                 
12 The 2-chloroethylamine derivative is presumably formed by displacement of the initially formed mesylate by 
the proximate nucleophilic nitrogen atom of the piperidine ring, producing an aziridinium ion, which can be 
opened by the chloride ion.  
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6.80 (s, 1 H, ArH), 6.65 (s, 0.4 H, ArH rotamer B), 6.63 (s, 0.6 H, ArH rotamer A), 5.34-5.16 
(m, 3 H), 4.95-4.88 (m, 0.4 H, NCH rotamer B), 4.88-4.80 (m, 0.6 H, rotamer A), 4.11-4.02 
(m, 0.4 H, NCH rotamer B), 4.02-3.93 (m, 0.6 H, rotamer A), 3.78 (s, 3 H, OCH3), 3.61 (s, 
1.3 H, OCH3 rotamer B), 3.55 (s, 1.7 H, OCH3 rotamer A), 2.52-2.37 (m, 1 H), 2.18-2.01 (m, 
1 H), 1.70-1.33 (m, 6 H), 1.31-1.18 (m, 2 H), 0.88 (t, 1.3 H, J = 7.5 Hz, OCH3 rotamer B), 
0.78 (t, 1.3 H, J = 7.5 Hz, OCH3 rotamer A).
 13C NMR (CD2Cl2, 100 MHz) δ (rotamers!) 
156.6, 147.6, 147.5, 145.5, 145.4, 137.7, 135.8, 135.2, 129.0, 128.9, 128.5, 128.4, 119.1, 
110.1, 109.8, 101.6, 101.5, 95.4, 67.6, 64.1, 64.0, 56.5, 56.4, 56.3, 55.5, 43.3, 43.2, 40.1, 40.0, 
39.9, 39.8, 28.7, 28.5, 27.1, 26.7, 21.6, 21.2, 8.1, 8.0. IR ν 3368 (w), 2940 (m), 2864 (w), 
1676 (s), 1485 (m), 1463 (m), 1434 (s), 1320 (m), 1210 (s), 1157 (m), 1113 (m), 1027 (w), 
757 (w). HRMS (ESI) C27H33N2O5
+ [M+H]+ calc. = 465.2384; [M+H]+ obs. = 465.2387. 
 
Hydroxy intermediate 12 (23.0 mg, 0.0495 mmol, 1.00 eq.) was dissolved in freshly distilled 
DCM (2.0 mL) and cooled to -78 °C. To the clear colorless solution was added dropwise 
freshly distilled boron trifluoride diethyl etherate13 (8 µL, 0.06 mmol, 1.2 eq.) to produce a 
dark red solution, which was quickly treated with freshly distilled trimethylsilyl cyanide (20 
µL, 0.15 mmol, 3.0 eq.). The reaction mixture was stirred at -78 °C for 5 minutes and then 
quickly transferred via cannula to saturated aq. NaHCO3 (10 mL) pre-cooled to 0 °C. The 
mixture was extracted with DCM (3 x 10 mL) and the combined organic layers were dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (hexane:EtOAc 3:2) to afford the cyano intermediate (22.2 mg, 
0.0469 mmol, 95%, Rf in EtOAc:Hexane 1:1 = 0.38, HRMS: [M+H]
+ calc. = 474.2387; 
[M+H]+ obs. = 474.2382) as a colorless oil, which was immediately used for subsequent 
transformations.  
 
The cyano intermediate (15.6 mg, 0.0329 mmol, 1.00 eq.) was dissolved in freshly distilled 
methanol (70 µL) and cooled to 0 °C at which 4.0 M HCl in cyclopentyl methyl ether (830 
µL) was added dropwise. The reaction mixture was stirred overnight for 12 hours at 0 °C, 
followed by hydrolyzing the corresponding Pinner salt by slowly adding water (10 mL) at 0 
°C. The resulting mixture was stirred for 60 minutes at room temperature and extracted with 
DCM (3 x 10 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography 
(hexane:EtOAc 3:1) to afford the pure Cbz-protected methyl ester intermediate (Rf in 
EtOAc:Hexane 3:2 = 0.53, HRMS: [M+H]+ calc. = 507.2490; [M+H]+ obs. = 507.2494), 
which was subsequently subjected to the general hydrogenolysis procedure giving the highly 
reactive free secondary amine (10.8 mg, 0.0290 mmol, 88%, HRMS: [M+H]+ calc. = 
373.2122; [M+H]+ obs. = 373.2119) as a light yellow oil.14  
 
Following a slight modification of a reported procedure,11 the free secondary amine (40.6 mg, 
0.109 mmol, 1.00 eq.) was dissolved in freshly distilled methanol (9.0 mL) in a Schlenk tube 
under nitrogen. The resulting solution was charged at room temperature under nitrogen with 
freshly distilled 2-bromoethanol (77.0 µL, 1.09 mmol, 10.0 eq.) and dry sodium carbonate 
(115 mg, 1.09 mmol, 10.0 eq.). The reaction mixture was stirred at reflux overnight for 12 
hours in the sealed Schlenk tube, after which the solvent was removed in vacuo. The crude 
was extracted with water (10 mL) and DCM (3 x 10 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by 
flash column chromatography (DCM:Ultra 97:3) to afford alkylation product 15 (42.2 mg, 
0.101 mmol, 93%, 78% overall from 12) as a light yellow oil. Rf (DCM:Ultra 7:3) = 0.51. 
1H 
                                                 
13 InCl3 can be used as an alternative as it produced comparable results.  
14 NMR analysis was unfeasible as the compound readily decomposed as solution in CD2Cl2. 
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NMR (CD2Cl2, 400 MHz): 8.31 (bs, 1 H, NH), 6.90 (s, 1 H, ArH), 6.87 (s, 1 H, ArH), 3.85 (s, 
3 H, OCH3), 3.84 (s, 3 H, OCH3), 3.83-3.78 (m, 1 H), 3.77 (s, 3 H, CO2CH3), 3.45 (td, 1 H, J 
= 10.3, 3.1 Hz), 3.17 (s, 1 H, NCH), 3.14-2.93 (m, 5 H), 2.26-2.15 (m, 2 H), 1.97-1.82 (m, 1 
H), 1.81-1.72 (m, 1 H), 1.68-1.55 (m, 2 H), 1.45 (td, 1 H, J = 13.6, 4.8 Hz), 1.19-1.08 (m, 1 
H), 1.01-0.90 (m, 1 H), 0.77 (t, 3 H, J = 7.5 Hz, CH2CH3). 
13C NMR (CD2Cl2, 100 MHz) δ 
174.0, 147.6, 145.9, 130.9, 129.5, 122.5, 113.0, 101.4, 95.6, 63.2, 58.7, 57.0, 56.7, 55.1, 52.9, 
52.9, 39.3, 38.6, 34.9, 30.4, 28.1, 22.4, 8.1. IR ν 3352 (w), 2936 (w), 2831 (w), 1733 (s), 1486 
(s), 1464 (m), 1295 (m), 1235 (m), 1201 (s), 1161 (s), 1121 (m), 1055 (w), 1034 (m), 956 (w). 
HRMS (ESI) C23H33N2O5
+ [M+H]+ calc. = 417.2384; [M+H]+ obs. = 417.2381. 
 
 
Methyl 3-ethyl-8,9-dimethoxy-2,3,4,6,11,12-octahydro-1H-indolizino[8,1]carbazole-5-
carboxylate (16) 
 
 
 
Following a slight modification of a reported procedure,11 primary alcohol 15 (40.1 mg, 
0.0963 mmol, 1.00 eq.) was dissolved in dry DCM (4.0 mL) and cooled to -20 °C. The 
solution was treated with methanesulfonyl chloride (15.0 µL, 0.193 mmol, 2.00 eq.), 
triethylamine (40.3 µL, 0.289 mmol, 3.00 eq.) and stirred at -20 °C for 60 minutes. The 
reaction mixture was diluted with DCM (10 mL) and extracted with saturated aq. NaHCO3 
(10 mL). The aqueous layer was extracted with additional portions of DCM (2 x 10 mL) and 
the combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
resulting yellow oil was dissolved in dry THF (4.0 mL) and cooled to 0 °C. Next was added 
dopwise at 0 °C a 0.3 M potassium tert.-butoxide solution in THF (1.60 mL, 0.481 mmol, 5.00 
eq.) and the mixture was stirred overnight for 14 hours, letting the reaction temperature 
slowly come to room temperature. The reaction mixture was quenched by adding a few drops 
of water, diluted with THF (5.0 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by flash column chromatography (DCM:Ultra 98:2) to afford 
pentacyclic product 16 (32.8 mg, 0.0823 mmol, 85%) as a light yellow oil. Rf (DCM:Ultra 
4:1) = 0.56. 1H NMR (CD2Cl2, 400 MHz): 8.75 (bs, 1 H, NH), 6.81 (s, 1 H, ArH), 6.49 (s, 1 
H, ArH), 3.79 (s, 6 H, OCH3), 3.72 (s, 3 H, CO2CH3), 3.14-3.06 (m, 1 H), 2.93-2.86 (m, 1 H), 
2.69 (d, 1 H, J = 14.9 Hz), 2.59-2.50 (m, 1 H), 2.45-2.36 (m, 2 H), 2.23 (dd, 1 H, J = 15.1, 2.0 
Hz), 1.99 (td, 1 H, J = 11.3, 6.5 Hz), 1.88–1.74 (m, 2 H), 1.64 (dd, 1 H, J = 11.3, 4.8, Hz), 
1.56–1.49 (m, 1 H), 1.32–1.20 (m, 1 H), 1.02-0.93 (m, 1 H), 0.69–0.54 (m, 4 H). 13C NMR 
(CD2Cl2, 100 MHz) δ 169.4, 169.2, 149.8, 144.3, 137.7, 129.5, 108.0, 96.2, 93.0, 73.2, 57.6, 
56.6, 56.3, 52.2, 51.3, 51.1, 45.7, 38.8, 33.5, 29.7, 25.9, 22.8, 7.5. IR ν 3362 (w), 2934 (m), 
2774 (w), 1674 (m), 1615 (s), 1498 (s), 1461 (m), 1291 (m), 1264 (s), 1204 (s), 1191 (s), 1164 
(s), 1137 (s), 1115 (m), 1048 (m). HRMS (ESI) C23H31N2O4
+ [M+H]+ calc. = 399.2278; 
[M+H]+ obs. = 399.2286. 
 
 
 
S12 
 
Jerantinine E (5) 
 
 
 
Dimethoxy starting material 16 (15.0 mg, 0.0376 mmol, 1.00 eq.) was dissolved in 
acetonitrile (1.5 mL) and cooled to 0 °C. To the mixture was slowly added a solution 
consisting of ceric ammonium nitrate (45.4 mg, 0.0830 mmol, 2.20 eq.) dissolved in water 
(1.0 mL) at 0 °C. The reaction was stirred for 5 minutes at 0 °C and then poured into a 1.0 M 
aq. sodium dithionite solution (10 mL) at 0 °C. The reaction mixture was stirred for 10 
minutes at 0 °C, diluted with DCM (10 mL) and extracted. The aqueous layer was washed 
with additional portions of DCM (3 x 10 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (DCM:Ultra 98:2) to afford jerantinine E (5, 11.4 mg, 0.0297 mmol, 79%) as 
a yellow oil. Rf (DCM:Ultra 4:1) = 0.48. 
1H NMR (CDCl3, 400 MHz): 8.76 (bs, 1 H, NH), 
6.83 (s, 1 H, ArH), 6.43 (s, 1 H, ArH), 5.27 (bs, 1 H, OH), 3.86 (s, 3 H, OCH3), 3.75 (s, 3 H, 
CO2CH3), 3.14-3.05 (m, 1 H), 2.94-2.85 (m, 1 H), 2.70 (d, 1 H, J = 15.0 Hz), 2.58-2.47 (m, 1 
H), 2.43-2.32 (m, 2 H), 2.24 (dd, 1 H, J = 15.1, 1.9 Hz), 2.03 (td, 1 H. J = 11.4, 6.4 Hz), 1.88–
1.74 (m, 2 H), 1.66 (dd, 1 H, J = 11.5, 4.6, Hz), 1.57–1.48 (m, 1H), 1.31–1.18 (m, 1 H), 1.02-
0.92 (m, 1 H), 0.68–0.54 (m, 4 H). 13C NMR (CD2Cl2, 100 MHz) δ 169.5, 169.2, 146.4, 
140.5, 136.8, 130.5, 108.9, 95.2, 92.9, 73.3, 56.9, 56.1, 52.1, 51.3, 51.2, 45.8, 38.9, 33.4, 29.7, 
25.9, 22.9, 7.5. IR ν 3370 (w), 2934 (w), 2776 (w), 1671 (m), 1606 (s), 1494 (s), 1441 (m), 
1266 (s), 1196 (s), 1165 (s), 1136 (s), 1114 (m), 1047 (w). HRMS (ESI) C22H29N2O4
+ [M+H]+ 
calc. = 385.2122; [M+H]+ obs. = 385.2113. 
 
 
As shown below in Figure S1, the 1H NMR spectrum of synthesized jerantinine E is identical 
to the 1H NMR spectrum of jerantinine E isolated from the Malayan plant Tabernaemontana 
corymbosa.15   
 
 
                                                 
15 The isolation 1H NMR spectrum of jerantinine E was kindly provided by Prof. T. S. Kam through a personal 
communication. The NMR data of isolated jerantinine E is summarized in the manuscript by Prof. Kam and co-
workers: K. H. Lim, O. Hiraku, K. Komiyama, T. S. Kam, J. Nat. Prod. 2008, 71, 1591-1594. 
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Figure S1. The 1H NMR spectrum of jerantinine E isolated from Tabernaemontana 
corymbosa (A) and the synthesized jerantinine E 1H NMR spectrum (B). 
 
 
Separation of the Enantiomers by Chiral HPLC  
 
The two enantiomers of jerantinine E were separated by chiral HPLC on a JASCO HPLC 
system with an AS2055 Autosampler, a PU 2089 Pump, a UV 2075 detector and a SEDEX 85 
(SEDERE) detector using an analytical CHIRALPAK IB column from DAICEL Chemical 
Industries Ltd. A mixture of HPLC grade hexane:isopropanol 98:2 (no additives) was used as 
mobile phase. The flow rate was set to 2.0 mL per minute with an acquisition time of 20 
minutes per run. Under the optimized separation conditions, 50 µL of a mixture consisting of 
approximately 2 mg jerantinine E dissolved in 1.5 mL hexane:isopropanol 9:1 were injected 
per run. Shown below in Figure S2 is a representative HPLC trace of a separation run (A), as 
well as traces of the two purified enantiomers (B and C).  
A 
B 
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Figure S2. HPLC traces of racemic jerantinine E (A) and the two enantiomers (+)-jerantinine 
E (B) and (-)-jerantinine E (C). 
 
Both enantiomers were analyzed for their optical rotatory power, which indicated that the first 
enantiomer (Figure S2, B) is non-natural, (+)-jerantinine E (>95%ee; [α]D25.0 +229 at c 0.05 
in CHCl3) and the second enantiomer (Figure S3, C) is naturally occurring (-)-jerantinine E 
(>90%ee; [α]D25.0 -237 at c 0.06 in CHCl3).16  
 
We note that the small contamination (approximately 5%) of (+)-jerantinine E in the sample 
of (-)-jerantinine E is negligible due to its minimal bio-activity.   
 
 
                                                 
16 The manuscript describing the isolation of jerantinine E reports that the [α]D25.0 is -357 at c 0.10 in CHCl3: K. 
H. Lim, O. Hiraku, K. Komiyama, T. S. Kam, J. Nat. Prod. 2008, 71, 1591-1594. 
A 
B 
C 
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5. Biological Evaluation of Jerantinine E (5) 
 
5.1 Evaluation of Jerantinine E (5) in Human Cancer Cell Lines17 
 
 
General Information for the Evaluation of Jerantinine E (5) in Cellular Assays 
 
The cellular assays were performed on two human-derived breast cancer cell lines and two 
human-derived lung cancer cell lines. One moderately invasive cell line was selected from an 
invasive breast ductal carcinoma (MCF-7), whereas the second breast cancer cell line was 
highly invasive (MDA-MB-231).[18] A human adenocarcinoma cell line (A549) derived from 
alveolar epithelial cells and an adenosquamous carcinoma cell line (HTB-178) were selected 
as lung cancer models.[19]  
 
Dose-Dependent Cytotoxic Effect of Jerantinine E (5)  
 
Cell lines A549, HTB-178, MCF-7 and MDA-MB-231 were obtained through the American 
Tissue Culture Collection (Manassas, VA, USA) and cell culture reagents and materials were 
purchased from Invitrogen. Cell lines A549, MCF-7 and MDA-MB-231 were grown in 
Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g/L glucose, 10% heat-
inactivated fetal calf serum (FCS) and penicillin/streptomycin. HTB-178 cells were grown in 
complete Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 20% 
FCS and penicillin/streptomycin.  
 
Cells were grown for 24 hours in 48 well plates (250 µL/well), after which the medium was 
exchanged with jerantinine E (5) containing medium at the indicated concentrations (prepared 
from stock solutions of either 1900 mg/L or 770 g/mL jerantinine E (5)), followed by an 
incubation for 24 or 72 hours. At the end of corresponding incubation periods, cell viability 
was evaluated using the MTT assay. As such, 10 µL aliquots of a solution consisting of 5 
mg/mL MTT (3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyltetrazolium bromide) in PBS were 
added to each well, followed by incubation for a 90 minutes. The cell culture supernatants 
were removed and the cells were treated with 250 µL of 2-propanol/0.04 N HCl  (5 mL of 4 
M HCl were diluted in 2-propanol until a final volume of 500 mL) and incubated for 15 
minutes, after which 200 µL were transferred into a fresh 96 well plate. Absorbance 
measurements were carried out at 540 nm in a multi-well plate spectrophotometer (Synergy 
HT, Biotek) and compared with the values of control wells (i.e. no jerantinine E (5) present in 
the cell medium). All experiments were conducted in triplicate wells and repeated twice to 
report the mean ± the standard deviation. 
 
 
 
 
 
 
                                                 
17 Performed by Mr. Davide Staedler under the supervision of Dr. MER Sandrine Gerber-Lemaire at the 
Laboratory of Synthesis and Natural Products at EPFL. 
18 D. Staedler, E. Idrizi, B. H. Kenzaoui, L. Juillerat-Jeanneret, Cancer Chemoth. Pharm. 2011, 68, 1161-1172. 
19 D. Staedler, T. Magouroux, R. Hadji, C. Joulaud, J. Extermann, S. Schwungi, S. Passemard, C. Kasparian, G. 
Clarke, M. Gerrmann, R. Le Dantec, Y. Mugnier, D. Rytz, D. Ciepielewski, C. Galez, S. Gerber-Lemaire, L. 
Juillerat-Jeanneret, L. Bonacina, J. P. Wolf, Acs Nano 2012, 6, 2542-2549. 
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Racemic Jerantinine E (5) in Human-Derived Breast Cancer Cell Lines  
 
 
Figure S3. Cytotoxic effect of (±)-jerantinine E (5) on the survival of human-derived breast 
cancer cell lines. Human MDA-MB-231 (black bars) and MCF-7 (grey bars) breast cancer 
cells were exposed for 24 (A) or 72 hours (B) to increasing concentrations (0.5, 2, and 6 
µg/mL) of (±)-jerantinine E (5). The experiments were conducted in triplicate wells and 
repeated twice to report the mean ± the standard deviation. Cells treated with (±)-jerantinine E 
(5) were compared to untreated cells using the student’s t-test: ** p <0.01; *** p <0.001. The 
obtained IC50-values after 24 and 72 hours are tabulated in part C. 
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Racemic Jerantinine E (5) in Human-Derived Lung Cancer Cell Lines  
 
 
Figure S4. Cytotoxic effect of (±)-jerantinine E (5) on the survival of human-derived lung 
cancer cell lines. Human A549 (black bars) and HTB-178 (grey bars) lung cancer cells were 
exposed for 24 (A) or 72 hours (B) to increasing concentrations (0.5, 2, and 6 µg/mL) of (±)-
jerantinine E (5). The experiments were conducted in triplicate wells and repeated twice to 
report the mean ± the standard deviation. Cells treated with (±)-jerantinine E (5) were 
compared to untreated cells using the student’s t-test: * p <0.05; ** p <0.01; *** p <0.001. 
The obtained IC50 values after 24 and 72 hours are tabulated in part C. 
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Non-Natural (+)-Jerantinine E (5) in Human-Derived Breast Cancer Cell Lines  
 
Figure S5. Cytotoxic effect of (+)-jerantinine E (5) on the survival of human-derived breast 
cancer cells. 
 
Human MDA-MB-231 (black bars) and MCF-7 (grey bars) breast cancer cells were exposed 
for 24h (A) or 72h (B) to increasing concentrations (0.5, 2 and 6 µg/mL) of (+)-jerantinine E 
(5). The experiments were conducted in triplicate wells and repeated twice to report the mean 
± the standard deviation. Cells treated with (+)-jerantinine E (5) were compared to untreated 
cells using the student’s t-test and showed no significant differences.  
 
 
Non-Natural (+)-Jerantinine E (5) in Human-Derived Lung Cancer Cell Lines 
 
Figure S6. Cytotoxic effect of (+)-jerantinine E (5) on the survival of human-derived breast 
cancer cells. 
 
Human A549 (black bars) and HTB-178 (grey bars) breast cancer cells were exposed for 24h 
(A) or 72h (B) to increasing concentrations (0.5, 2 and 6 µg/mL) of (+)-jerantinine E (5). The 
experiments were conducted in triplicate wells and repeated twice to report the mean ± the 
standard deviation. Cells treated with (+)-jerantinine E (5) were compared to untreated cells 
using the student’s t-test: * p <0.05. 
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Natural (-)-Jerantinine E (5) in Human-Derived Breast Cancer Cell Lines  
 
 
Figure S7. Cytotoxic effect of (-)-jerantinine E (5) on the survival of human-derived breast 
cancer cell lines. Human MDA-MB-231 (black bars) and MCF-7 (grey bars) breast cancer 
cells were exposed for 24 (A) or 72 hours (B) to increasing concentrations (0.5, 2, and 6 
µg/mL) of (±)-jerantinine E (5). The experiments were conducted in triplicate wells and 
repeated twice to report the mean ± the standard deviation. Cells treated with (-)-jerantinine E 
(5) were compared to untreated cells using the student’s t-test: *** p <0.001. The obtained 
IC50-values after 24 and 72 hours are tabulated in part C. 
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Natural (-)-Jerantinine E (5) in Human-Derived Lung Cancer Cell Lines  
 
 
Figure S8. Cytotoxic effect of (-)-jerantinine E (5) on the survival of human-derived lung 
cancer cell lines. Human A549 (black bars) and HTB-178 (grey bars) lung cancer cells were 
exposed for 24 (A) or 72 hours (B) to increasing concentrations (0.5, 2, and 6 µg/mL) of (-)-
jerantinine E (5). The experiments were conducted in triplicate wells and repeated twice to 
report the mean ± the standard deviation. Cells treated with (±)-jerantinine E (5) were 
compared to untreated cells using the student’s t-test: * p <0.05; *** p <0.001. The obtained 
IC50 values after 24 and 72 hours are tabulated in part C. 
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Cell Migration Assays 
 
The A549, HTB-178, MCF-7 and MDA-MB-231 cell lines were grown as described above. 
The cells were diluted in 100 µL of corresponding cell culture medium (300'000 cells/mL) 
containing jerantinine E (5) at the desired concentration and added to the upper chamber of a 
two-chamber Transwell device (6.5 mm diameter, 8.0 µm pore size polyethylene membrane, 
Falcon, BD). The lower Transwell chamber contained 600 µL of the corresponding cell 
culture medium and jerantinine E (5) at the desired concentration. After 15 hours of 
incubation, the cell layers were fixed in 4% formaldehyde in PBS and cells on the upper side 
of the membrane were removed by swiping with a damp cotton swab. The membrane was 
rinsed with PBS and stained for 10 minutes with 0.05% crystal violet in 1.5% glacial acetic 
acid. After washing with PBS, cells of one field of the lower side of the membrane were 
counted under a microscope at a 200x magnification. Experiments were conducted in 
duplicate and repeated twice to report the mean ± the standard deviation. 
 
 
Figure S9. Migratory effect of (±)-jerantinine E (5) on the migration of human-derived cancer 
cell lines. Human-derived MDA-MB-231 (black bars) and MCF-7 (grey bars) breast cancer 
cells (A) and human-derived A549 (black bars) and HTB-178 (grey bars) lung cancer cells 
(B) were exposed for 15 hours to 2 or 6 µg/mL of (±)-jerantinine E (5). The number of 
migrating cells through a transwell device was determined through two independent 
experiments to report the mean ± the standard deviation. Migrating cells treated with (±)-
jerantinine E (5) were compared to untreated cells using the student’s t-test (we note that all 
comparisons were statistically significant with ***p <0.001).  
 
Inhibition of cell migration was observed for all four cancer cell lines after 15 h exposure at 2 
and 6 µg/mL concentrations of (±)-jerantinine E (5) (Figure S9). The inhibition was dose-
dependent and particularly marked in breast cancer cells (Figure S9, A). The cell survival 
after 15 hours of (±)-jerantinine E (5) exposure to the corresponding cell lines was determined 
to investigate if the antimigratory effect is simply due to cytotoxicity. The results of this 
control experiment are summarized below in Figure S10 and indicated that the antimigratory 
effect is not solely due to cytotoxicity as the observed inhibition of cell migration was much 
more significant than the observed cytotoxic effect after 15 hours. 
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Figure S10. Cytotoxic effect of (±)-jerantinine E (5) on the survival of human-derived breast 
and lung cancer cell lines. Human-derived MDA-MB-231 (black bars) and MCF-7 (grey bars) 
breast cancer cells (A) and human-derived A549 (black bars) and HTB-178 (grey bars) lung 
cancer cells (B) were exposed for 15 hours to 2 or 6 µg/mL of (±)-jerantinine E (5). The 
experiments were conducted in triplicate wells and repeated twice to report the mean ± the 
standard deviation. Cells treated with (±)-jerantinine E (5) were compared to untreated cells 
using the student’s t-test: *** p <0.001. 
 
 
 
5.2 Impedance and Cell Staining Assays20 
 
Cytotoxicity assay: A MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
assay was used to determine the IC50 of (±)-jerantinine E (5) with L-929 (DSMZ ACC 2) 
mouse fibroblast and PtK2 (ATCC CCL-56) potoroo cell lines (Figure S11). As such, 60 µL 
of serial dilutions of (±)-jerantinine E (5) (stock concentration 1 mg/mL in MeOH) were 
added to 120 µL aliquots of a cell suspension (50 000 mL–1) in 96-well microplates. Blank 
and solvent controls were incubated under identical conditions. After 5 days, 20 µL MTT in 
phosphate buffered saline (PBS) were added to a final concentration of 0.5 mg mL–1. After 2 
h, the resulting precipitate of formazan crystals was centrifuged, and the supernatant 
discarded. The precipitate was washed with 100 µL PBS and dissolved in 100 µL isopropanol 
containing 0.4% hydrochloric acid. The microplates were gently shaken for 20 min to ensure 
a complete dissolution of the formazan and finally measured at 595 nm using an ELISA plate 
reader. All experiments were carried out in two parallels. Activity values were calculated as 
the mean with respect to the controls set to 100%. Cell lines were grown in media 
recommended by the supplier (DSMZ or ATCC). 
 
 
                                                 
20 Performed by Ms. Aruna Raja, Dr. Raimo Franke and Dr. Florenz Sasse at the Helmholtz Centre for Infection 
Research in Braunschweig. 
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Figure S11: Cytotoxicity of (±)-jerantinine E (5) with mouse fibroblast cells (L-929) and rat 
kangaroo kidney cells (PtK2) indicating an IC50 of 14 µg/ml.  
 
Impedance profiling  
 
The impedance measurements were performed with small modifications on a RT-CES system 
(xCelligence) from Acea Biosciences (Roche), which has been described previously.21 For 
time-dependent cell response profiling, 60 µL of Dulbecco modified Eagle medium (DMEM) 
were added to 96-well E-Plate to obtain background readings followed by the addition of 120 
µL cell suspension of L-929 cells. After each step, the E-Plates were incubated for 30 minutes 
at room temperature and then placed on the reader in the incubator for continuous recording 
of impedance as reflected by the cell index. After 24 hours of incubation the cells were treated 
with the compounds. To prepare (±)-jerantinine E (5) for screening, the stock solution (10 
mM in DMSO) was diluted with DMEM to get a final test concentration of the IC90 and less 
than 0.1 % DMSO. 1 µL of each prepared solution was then transferred into the 96-well E-
Plate. Each E-plate also contained wells with DMSO only as a solvent control. All 
measurements were performed in triplicates and run for 5 days. The time-dependent cellular 
response profiles (TCRP) were recorded by the Roche RTCA Software, Version 1.2. Data 
processing and mining workflow was implemented in the statistical programming language R, 
Version 2.12.2 (R Development Core Team, 2011). The following additional R packages were 
used in addition: class22, gplots23 and MASS.21 For the development of the R code the 
integrated development environment R Studio, Version 0.94.92, was used. The workflow 
                                                 
21 a) K. Solly, X. Wang, X. Xu, B. Strulovici, W. Zheng, Assay Drug Dev. Technol. 2004, 2, 363;  b) J. M. 
Atienza, N. Yu, S. L. Kirstein, B. Xi, X. Wang, X. Xu, Y. A. Abassi, Assay Drug Dev. Technol. 2006, 4, 597;  c) 
Y. A. Abassi, B. Xi, W. Zhang, P. Ye, S. L. Kirstein, M. R. Gaylord, S. C. Feinstein, X. Wang, X. Xu, Chem. 
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starts by importing the raw impedance data which is provided by the RTCA software as cell 
index (CI) data. The CI is already background corrected and is calculated as follows (Eq. 1):24 
Eq. 1:     CI(t)=
Rt-Rb 
Zn
 
where CI(t) is the cell index at time point t, Rt is defined as measured electrode impedance of 
the well with the cells in the medium at a certain time point and Rb as measured background 
impedance of the well with the cell medium alone. Zn is a frequency factor which corrects for 
different frequencies of the alternating voltage the xCelligence system can use, with the 
standard setting being Zn=15. The raw data were imported into R and normalized as suggested 
by Abassi and colleagues by dividing the cell indices for each time point after compound 
addition by the cell index at a reference time point (Eq. 2).23 As reference time point, the last 
measurement before compound addition was taken. For subsequent analysis, only the 
measurements starting at the reference time point (with normalized cell index = 1) and later 
were considered. 
Eq. 2:      NCI=
CIt 
CIt(reference)
 
The reference compounds and (±)-jerantinine E (5) with unknown mode of action were 
measured as triplicates which were randomly distributed over the microtiter plates (using 
sampling without replacement in R) to avoid batch effects. 
Detection and removal of outliers was carried out using the median polishing procedure. The 
central idea of the data mining concept is to use cubic smoothing splines for the 
approximation of the impedance data and as dimension reduction technique. This approach 
has the benefit of avoiding the curse of dimensionality and the Runge phenomenon that 
occurs for high polynomials, while keeping the complexity of the data set. The smooth.spline 
function of R was used for TCRP approximation. As set of descriptors the spline basis 
coefficients were extracted to construct a distance matrix that was used for hierarchical cluster 
analysis. A heatmap was constructed that displays the Z-transformed values of the 22 
descriptors (= basis spline coefficients). Hierarchical cluster analysis of the reference 
compounds together with the compound of unknown mode of action was carried out. Co-
clustering of the compound of unknown mode of action with reference compounds with 
known activity class label is used to predict the mode of action. The results of the impedance 
profiling are shown below in Figure S12. 
 
                                                 
24 N. Ke, B. Xi, P. Ye, W. Xu, M. Zheng, L. Mao, M. J. Wu, J. Zhu, J. Wu, W. Zhang, J. Zhang, J. Irelan, X. 
Wang, X. Xu, Y. A. Abassi, Anal. Chem. 2010, 82, 6495. 
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Figure S12. Cluster analysis based on impedance monitoring curves shows that the closest 
neighbour of (±)-jerantinine E (5, JerE) is colchicin, a known tubulin disrupting agents. 
 
 
 
Cell Staining: PtK2 cells (ATCC CCL-56) were grown in 750 µL medium in 4-well plates 
(Nunc) on glass coverslips, and incubated with (±)-jerantinine E (5, 2 µg mL–1) overnight. 
For α-tubulin staining, cells were fixed with cold (–20 °C) MeOH/acetone (1:1) for 10 min 
and incubated with a mouse anti α-tubulin antibody (1:100; Sigma) followed by a secondary 
Alexa Fluor 488 labelled goat anti-mouse IgG antibody (1:200; Molecular Probes) and 
mounted in ProLong Antifade Gold (Molecular Probes), which included DAPI (4',6-
diamidino-2-phenylindole) to stain the nuclei. The results of the immunofluorescent staining 
are depicted below in Figure S13. 
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Figure S13. Immunofluorescent staining of untreated PtK2 kidney cells (control/MeOH) and 
cells exposed to 2 µg/mL, 6 µg/mL and 10 µg/mL (±)-jerantinine E (5) showing the effect on 
microtubules (green) and the cell nucleus (blue). 
 
 
 
 
 
 
 
 
 
5.3 Tubulin Polymerization Assay17 
 
Effects on tubulin polymerization were assessed at 0.5, 1, 3, 5 and 10 µM for both 
enantiomers and racemic jerantinine E (5) using the Tubulin Polymerization Assay Kit 
purchased from Cytoskeleton (cat. no. BK011P). The assay was carried out according to the 
corresponding protocol instructions. The compounds paclitaxel and colchicine (at 3 µM; two 
different stocks of colchicine, purchased from Sigma-Aldrich, were freshly prepared and 
tested in two independent duplicates) were used as tubulin polymerization enhancer and 
inhibitor controls, respectively.  The assay was performed applying the conditions for tubulin 
polymerization inhibition detection. Stock solutions of test compounds were prepared at 2 
mM in DMSO. Measurements were obtained in duplicate form and repeated twice. The IC50–
values were calculated form the dose-response curve during the growth phase. Summarized 
below are the IC50–values of both enantiomers and racemic jerantinine E (5) as well as the 
inhibition of tubulin polymerization values at 3 µM (including colchicine). 
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IC50–values of (±)-jerantinine E, (-)-jerantinine E and (+)-jerantinine E: 
 
Compound IC50 (µg/mL) IC50 (µM) 
(±)-Jerantinine E 3.89 ± 0.11 10.1 ± 0.28 
(+)-Jerantinine E >> 4 >> 10 
(-)-Jerantinine E 0.171 ± 0.01 0.446 ± 0.02 
 
 
Inhibition of tubulin polymerization at 3 µM: comparison between jerantinine E, (-)-
jerantinine E, (+)-jerantinine E and colchicine. 
 
Compound % of inhibition 
(±)-Jerantinine E 18.4% ± 0.7% 
(+)-Jerantinine E 11.8% ± 0.5% 
(-)-Jerantinine E 79.1% ± 2.3% 
Colchicine 75.0% ± 2.5% 
 
We note that (-)-jerantinine E (5) was a more effective inhibitor of tubulin polymerization 
than colchicine (the difference was statistically significant with *p<0.05 (Student t test)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Spectra of New Compounds 
 
Shown below are the corresponding 1H, 13C NMR and IR spectra of the above fully 
characterized new compounds. All 1H NMR spectra were obtained at 400 MHz and all 13C 
NMR spectra were obtained 101 MHz. Deuterated chloroform or dichloromethane, as 
indicated above in the tabulated NMR data for each fully characterized compound, were used 
as solvent to carry out the corresponding NMR characterization.  
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